Research programme: neuropsychiatric disorder therapies - Eli Lilly/PsychoGenics
Latest Information Update: 11 Sep 2009
At a glance
- Originator Eli Lilly; PsychoGenics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Neurological disorders; Psychiatric disorders
Most Recent Events
- 01 Feb 2008 Eli Lilly and PsychoGenics enter into an additional drug discovery agreement for the treatment of neuropsychiatric disorders
- 21 Dec 2006 Early research in Psychiatric disorders in USA (unspecified route)